SEC Form 4 · accession 0001479290-18-000093
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cyril Allouche
Officer — Principal Financial Officer
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | J | 393 | $23.3325 | A | 5,143 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mr. Allouche under the Issuer's 2014 Employee Stock Purchase Plan on June 29, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).